THERAVAC: Evaluation of a new therapeutic vaccination strategy for HIV infection

• Unité de recherche: PCRD EU
• Numéro de projet: 02.0455
• Titre du projet anglais: THERAVAC: Evaluation of a new therapeutic vaccination strategy for HIV infection

Mots-clé (Anglais)

Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects

Autre Numéro de projet (Anglais)

EU project number: QLK2-CT-2002-01299

Programme de recherche (Anglais)

EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases

Description succincte (Anglais)

See abstract

Autres indications (Anglais)

Full name of research-institution/enterprise:
Centre hospitalier universitaire vaudois CHUV
Division d'immunologie et d'allergie
Laboratoire d'immunopathologie du SIDA

Résumé des résultats (Abstract) (Anglais)

Highly active antiretroviral therapy (HAART) dramatically decreases in HIV-related morbidity but does not eradicate HIV and is associated with severe toxicities. To improve clinical management of HIV infection the TheraVac Demonstration Project will evaluate a new strategy of immunotherapy using highly attenuated poxvirus-based anti-HrV vaccines (NYVAC/MVA) in phase I/II clinical trials in HIV-infected patients.

The objectives of the Project are to demonstrate:
1) the safety of these vaccines in HIV-infected patients under HMRT;
2) their capacity to increase numbers and breadth of HIV-specific T cells in order to restore a strong immune control of HIV, compared to the Canary pox vaccine;
3) to allow prolonged interruptions of treatments.

A principal deliverable of TheraVac is to show that the collaboration of new vaccines produced in Europe and antiretroviral scan limit time on therapy and associated drug toxicity and costs.

Références bases de données (Anglais)

Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. [phone]
Swiss Project-Number: 02.0455